Valneva (NASDAQ:VALN) Shares Gap Up – Time to Buy?

Valneva SE (NASDAQ:VALN)’s share price gapped up before the market opened on Friday . The stock had previously closed at $6.86, but opened at $7.11. Valneva shares last traded at $7.31, with a volume of 860 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Valneva in a research report on Friday, February 28th.

Valneva Stock Performance

The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock’s 50-day moving average is $5.86 and its 200 day moving average is $5.64. The firm has a market cap of $574.52 million, a P/E ratio of -54.38 and a beta of 1.93.

Hedge Funds Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA acquired a new position in shares of Valneva SE (NASDAQ:VALN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.